Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

Authors: Anna Rosa Garbuglia, Alessia Monachetti, Claudio Galli, Rosella Sabatini, Monica Lucia Ferreri, Maria Rosaria Capobianchi, Patrizia Bagnarelli

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

A good correlation between HCV core antigen (HCVAg) and different HCV-RNA assays has been described, but little data are available in HCV/HIV co-infection. We aimed to evaluate HCVAg in comparison with HCV-RNA and to determine their kinetics during antiviral treatment in selected HCV/HIV co-infected patients.

Methods

355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes. The differences between percentages were evaluated by chi square or Fisher’s exact test, while mean and median values were compared by Student’s t test or the Mann–Whitney test, respectively. All differences were considered significant for a p value <0.05.

Results

HCVAg was detectable on 288/315 sera (91.4%) positive for HCV-RNA and in 5 out of40 (12.5%) sera with undetectable HCV-RNA for a total concordance of 90.1%. The correlation was fair both in untreated (r = 0.742) and in treated (r = 0.881) patients and stronger for genotypes 1 and 4 than for genotype 3. Both HCV-RNA and HCVAg levels were significantly higher (p = 0.028 and p = 0.0098, respectively) in patients infected by genotype 1 than by genotype 3. The mean ratio of Log values between HCV-RNA (IU/mL) and HCVAg (fmol/liter) was 2.27 ± 1.09 in untreated and 2.20 ± 0.82 in treated patients (p = n.s.),consistent with a sensitivity of HCVAg corresponding to about 1,000 IU/mL of HCV-RNA, and ranged from 2.21 to 2.32 among HCV genotypes with no significant differences; five samples (1.4%; 2 genotype 1a or 1c, 3 genotype 3a) showed highly divergent values. The analysis of 18 monitoring profiles from patients treated with PEG-IFN and Ribavirin showed similar trends, except in one case in which relapse could be predicted by HCVAg and not by HCV-RNA.

Conclusion

These results suggest that HCVAg represents an adequate tool for determining an ongoing HCV infection also in HIV co-infected patients, with lower costs and faster turnaround time than HCV-RNA.
Appendix
Available only for authorised users
Literature
1.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989, 244: 359-362. 10.1126/science.2523562.CrossRefPubMed
2.
Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4.CrossRefPubMed
3.
Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok ASF, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HLA, et al: The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011, 18 (suppl. 1): 1-16.CrossRefPubMed
4.
European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011, 55: 245-264.CrossRef
5.
Hofmann WP, Sarrazin C, Zeuzem S: Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012, 109: 352-358.PubMed
6.
Halfon P, Bourlière M, Pénaranda G, Khiri H, Ouzan D: Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol. 2006, 44: 2507-2511. 10.1128/JCM.00163-06.CrossRefPubMedPubMedCentral
7.
Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR: Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol. 2009, 47: 2872-2878. 10.1128/JCM.02329-08.CrossRefPubMedPubMedCentral
8.
Bortoletto G, Campagnolo D, Mirandola S, Comastri G, Severini L, Pulvirenti FR, Alberti A: Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. J Clin Virol. 2011, 50: 217-220. 10.1016/j.jcv.2010.11.010.CrossRefPubMed
9.
Bossler A, Gunsolly C, Pyne MT, Rendo A, Rachel J, Mills R, Miller M, Sipley J, Hillyard D, Jenkins S, Essmyer C, Young S, Lewinski M, Rennert H: AmpliPrep/COBAS TaqMan® automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. J Clin Virol. 2011, 50: 100-103. 10.1016/j.jcv.2010.10.020.CrossRefPubMed
10.
Chevaliez S: Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect. 2011, 17: 116-121. 10.1111/j.1469-0691.2010.03418.x.CrossRefPubMed
11.
Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K: A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods. 2009, 157: 8-14. 10.1016/j.jviromet.2008.12.009.CrossRefPubMed
12.
Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M: Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol. 2010, 48: 1161-1168. 10.1128/JCM.01640-09.CrossRefPubMedPubMedCentral
13.
Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, Galli S, Terlenghi L, Olivares M, Bagnarelli P, Costantini A, De Conto F, Sainz M, Galli C, Manca N, Landini MP, Dettori G, Chezzi C: Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol. 2011, 51: 260-265.CrossRef
14.
Descamps V, Op de Beck A, Plassart C, Brochot E, Francois C, Helle F, Adler M, Bourgeois N, Degré D, Duverlie G, Castelain S: Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol. 2012, 50: 465-468. 10.1128/JCM.06503-11.CrossRefPubMedPubMedCentral
15.
Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL: Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol. 2009, 46: 210-215. 10.1016/j.jcv.2009.08.014.CrossRefPubMed
16.
Kesly R, Polat H, Terzi Y, Kurtoglu MG, Uyar Y: Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol. 2011, 49: 4089-4093. 10.1128/JCM.05292-11.CrossRef
17.
Kamili S, Drobeniuk J, Araujo AC, Hayden TM: Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012, 55 (S1): S43-S48.CrossRefPubMed
18.
Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J: Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010, 48: 18-21. 10.1016/j.jcv.2010.02.012.CrossRefPubMed
19.
Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, Crovari P: Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV Core antigen. J Clin Microbiol. 2001, 39: 3110-3114. 10.1128/JCM.39.9.3110-3114.2001.CrossRefPubMedPubMedCentral
20.
Leary TP, Gutierrez RA, Muerhoff AS, Birkenmeyer LG, Desai SM, Dawson GJ: A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. J Med Virol. 2006, 78: 1436-1440. 10.1002/jmv.20716.CrossRefPubMed
21.
Mederacke I, Potthoff A, Meyer-Olson D, Meier M, Raupach R, Manns MP, Wedemeyer H, Tillmann HL: HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol. 2012, 53: 110-115. 10.1016/j.jcv.2011.11.009.CrossRefPubMed
22.
Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M: Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol. 2008, 46: 1901-1906. 10.1128/JCM.02390-07.CrossRefPubMedPubMedCentral
23.
Martró E, González V, Buckton AJ, Saludes V, Fernández G, Matas L, Planas R, Ausina V: Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5′ noncoding and nonstructural 5b genomic regions. J Clin Microbiol. 2008, 46: 192-197. 10.1128/JCM.01623-07.CrossRefPubMed
24.
Zanetti AR, Romanò L, Brunetto M, Colombo M, Bellati G, Tackney C: Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J Med Virol. 2003, 70: 27-30. 10.1002/jmv.10355.CrossRefPubMed
25.
Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H: Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol. 2005, 43: 186-191. 10.1128/JCM.43.1.186-191.2005.CrossRefPubMedPubMedCentral
26.
Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C: Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol. 2012, 55: 17-22. 10.1016/j.jcv.2012.05.008.CrossRefPubMed
27.
Loggi E, Cursaro C, Scuteri A, Grandini E, Martello Panno A, Galli S, Furlini G, Bernardi M, Galli C, Andreone P: Patterns of HCV-RNA and HCV Core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol. 2013, 56: 291-295. 10.1016/j.jcv.2012.11.012.CrossRef
28.
Schuettler CG, Thomas C, Discher T, Friese G, Lohmeyer J, Schuster R, Schaefer S, Gerlich WH: Variable ratio of hepatitis C virus RNA to viral Core antigen in patient sera. J Clin Microbiol. 2005, 42: 1977-1981.CrossRef
29.
Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV: Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol. 2010, 84: 10999-11009. 10.1128/JVI.00526-10.CrossRefPubMedPubMedCentral
30.
Murayama A, Sugiyama N, Watashi K, Masaki T, Suzuki R, Aizaki H, Mizuochi T, Wakita T, Kato T: Japanesereferencepanel of bloodspecimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol. 2012, 50: 1943-1949. 10.1128/JCM.00487-12.CrossRefPubMedPubMedCentral
31.
Durante-Mangoni E, Vallefuoco L, Sorrentino R, Lossa D, Perna E, Molaro R, Braschi U, Zampino R, Sodano G, Adinolfi LE, Utili R, Portella G: Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. J Med Virol. 2013, 85: 1913-1918. 10.1002/jmv.23672.CrossRefPubMed
32.
Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN: Is hepatitis C virus core antigen an adequate marker for community screening?. J Clin Microbiol. 2012, 50: 1989-1993. 10.1128/JCM.05175-11.CrossRefPubMedPubMedCentral
33.
Ergunay K, Sener B, Alp A, Karakaya J, Hascelick G: Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis. 2011, 70: 486-491. 10.1016/j.diagmicrobio.2011.04.011.CrossRefPubMed
34.
Ohshawa M, Kato K, Tanno K, Ikai K, Fujishima Y, Okayama A, Turin TC, Onoda T, Suzuki : Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients. J Epidemiol. 2011, 21: 491-499. 10.2188/jea.JE20100187.CrossRef
35.
Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C, UK Collaborative HIV Cohort (UK CHIC) Study: The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat. 2010, 17: 569-577.CrossRefPubMed
36.
Taylor LE, Swan T, Mayer KH: HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012, 55 (S1): s33-s42.CrossRefPubMedPubMedCentral
37.
Anggorowati N, Yano Y, Heriyanto DS, Hinonce HT, Utsumi T, Mulya DP, Subronto YW, Hayashi Y: Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. J Med Virol. 2012, 84: 857-865. 10.1002/jmv.23293.CrossRefPubMed
38.
Righi E, Beltrame A, Bassetti M, Lindstrom V, Mazzarello G, Dentone C, Di Biagio A, Ratto S, Viscoli C: Therapeutical aspects and outcome of HIV/HCV coinfectedpatients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection. 2008, 36: 358-361. 10.1007/s15010-008-7319-5.CrossRefPubMed
39.
Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, et al: A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Internat. 2011, 31 (suppl. 2): 30-60.CrossRef
40.
Stroffolini T, D’Egidio PF, Aceti A, Filippini P, Puoti M, Leonardi C, Almasio PL, and the DAVIS (Drug Addicted, HCV Prevalence in Italy) participating Centers: An epidemiological, observational, cross-sectional, multicenter study: Hepatitis C virus infection among drug addicts in Italy. J Med Virol. 2012, 84: 1608-1612. 10.1002/jmv.23370.CrossRefPubMed
41.
Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P: Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 2008, 197: 1558-1566. 10.1086/587843.CrossRefPubMed
42.
Shen T, Chen X, Zhang W, Xi Y, Cao G, Zhi Y, Wang S, Xu C, Wei L, Lu F, Zhuang H: A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients. PLoS ONE. 2011, 6: e23550-10.1371/journal.pone.0023550.CrossRefPubMedPubMedCentral
43.
Xu C-H, Shen T, Zheng J-J, Tu J, Zhang W-D, Lu F-M: Higher dN/dS ratios in the HCV core gene, but not in the E1/HVR1 gene, are associated with human immunodeficiency virus-associated immunosuppression. Arch Virol. 2012, 157: 2153-2162. 10.1007/s00705-012-1390-z.CrossRefPubMed
44.
Millum J, Menikoff J: Streamlining ethical review. Ann Intern Med. 2010, 2010 (153): 655-657.CrossRef
Metadata
Title
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
Authors
Anna Rosa Garbuglia
Alessia Monachetti
Claudio Galli
Rosella Sabatini
Monica Lucia Ferreri
Maria Rosaria Capobianchi
Patrizia Bagnarelli
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-222

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue

Research article

The use of the temporal scan statistic to detect methicillin-resistant Staphylococcus aureus clusters in a community hospital

Case report

Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection

Research article

Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature

Research article

A genome-wide association study of variants associated with acquisition of Staphylococcus aureus bacteremia in a healthcare setting

Research article

AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies

Research article

Risk factors for latent tuberculosis infection in close contacts of active tuberculosis patients in South Korea: a prospective cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits